Switzerland joins embryonic stem cell R&D (research and development) race:
This article was originally published in Clinica
Executive Summary
The Swiss population has overwhelmingly approved of new legislation permitting embryonic stem cell research, through a referendum that had been called with the aim of repealing, on ethical grounds, a law passed by the government in December 2003. Two-thirds (1,156,613 or 66.4%) of the votes cast backed the new law, while 33.6% (585,414 votes) went against. The approved law allows the use only of embryos left over from in vitro fertilisation. The government welcomed the result of the referendum, citing its importance for the major bioscience companies based in Switzerland, for the progress of medicine, especially with regard to potentially finding cures for conditions such as paraplegia, diabetes, myocardial infarction and Alzheimer's disease. The new law comes into force in March 2005.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.